Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL3162158 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665344 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665291 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7630144 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL12485521 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL973873 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832889-B1 | Process for the synthesis of benzothiophenes | LILLY CO ELI (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6713494-B1 | SUCH AS 6-HYDROXY-2-(4-HYDROXYPHENYL)-3-(4-(2-PIPERIDINYL-ETHOXY)BENZOYL)BENZOTHIOPHENE HYDROCHLORIDE SALT; OSTEO-POROSIS | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | LUKE WAYNE DOUGLAS (US) | 2002-11-21 | — | — | US | disclosed |
| US-6472531-B1 | SINGLE REACTION VESSEL ACYLATION AND DEETHERIFICATION PRODUCTION OF CRYSTALLINE, HIGH PURITY CHEMICAL INTERMEDIATES FOR SUCH AS PHARMACEUTICALS | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6399778-B1 | CRYSTALLINE SOLVATE | ELI LILLY AND COMPANY | 2002-06-04 | — | — | US | disclosed |
| EP-0842930-B1 | Process for the synthesis of benzothiophenes | LILLY CO ELI (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0693488-B1 | An improved process for preparing 3-(4-aminoethoxy-benzoyl)benzo beta -thiophenes | LILLY CO ELI (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-0888331-A4 | SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6008377-A | ACYLATING A N-DISUBSTITUED-PHENYLOXYETHYLAMINE CHLORO OR BROMO SALT WITH A BENZOTHIOPHENE DERIVATIVE IN PRESENCE OF TRIBOROCHLORIDE OR BROMIDE, DEALKYLATING ONE OR MORE PHENOLIC GROUP OF THE PRODUCT WITH ADDITIONAL BOROHALIDE | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| US-5994547-A | Process for preparing benzo[b]thiophenes | ELI LILLY AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| US-5629425-A | NONSTEROIDAL ANTIESTROGEN | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5523416-A | Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0693488-A1 | An improved process for preparing 3-(4-aminoethoxy-benzoyl)benzo beta -thiophenes | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5445941-A | Using nucleic acids from the promoter regions of transforming growth factor beta genes comprising novel regulatory elements designated \"raloxifene responsive elements\ | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0062504-B1 | PROCESS FOR PREPARING 3-(4-AMINOETHOXYBENZOYL)BENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0062505-B1 | A PROCESS FOR PREPARING ACYLATED BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1985-07-24 | — | — | EP | disclosed |
| US-4380635-A | Synthesis of acylated benzothiophenes | ELI LILLY AND COMPANY (US) | 1983-04-19 | — | — | US | disclosed |
| US-4358593-A | BY ACYLATION OF PROTECTED 6-HYDROXY,2-(4-HYDROXYPHENYL) BENZO (B)THIOPHENE USING A FRIEDEL CRAFTS CATALYSTS; HYDROLYSIS | ELI LILLY AND COMPANY (US) | 1982-11-09 | — | — | US | disclosed |
| EP-0062504-A1 | Process for preparing 3-(4-aminoethoxybenzoyl)benzo(b)thiophenes | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| EP-0062505-A1 | A process for preparing acylated benzothiophenes | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | HTR3B, HTR3C, HTR2B | ESR1 4320/4885ESR2 4181/4885MEN1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.